Foundations Investment Advisors LLC lowered its holdings in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 8.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,286 shares of the company’s stock after selling 717 shares during the quarter. Foundations Investment Advisors LLC’s holdings in ARK Genomic Revolution ETF were worth $212,000 as of its most recent filing with the SEC.
Other institutional investors also recently made changes to their positions in the company. Chris Bulman Inc acquired a new stake in shares of ARK Genomic Revolution ETF in the 2nd quarter worth approximately $36,000. EverSource Wealth Advisors LLC purchased a new stake in ARK Genomic Revolution ETF during the first quarter worth $49,000. Larson Financial Group LLC grew its holdings in ARK Genomic Revolution ETF by 4,576.1% in the second quarter. Larson Financial Group LLC now owns 3,320 shares of the company’s stock valued at $78,000 after purchasing an additional 3,249 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in ARK Genomic Revolution ETF by 9.4% in the second quarter. First Horizon Advisors Inc. now owns 4,650 shares of the company’s stock valued at $109,000 after purchasing an additional 398 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in shares of ARK Genomic Revolution ETF in the second quarter valued at $222,000.
ARK Genomic Revolution ETF Stock Performance
ARK Genomic Revolution ETF stock opened at $23.30 on Friday. The stock has a 50 day simple moving average of $25.31 and a 200-day simple moving average of $25.12.
About ARK Genomic Revolution ETF
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Articles
- Five stocks we like better than ARK Genomic Revolution ETF
- What Are Growth Stocks and Investing in Them
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Consumer Staples Stocks, Explained
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
